A Randomized, Double-Blind Phase Iii Trial Of Niraparib Maintenance Treatment In Patients With Hrd Plus Advanced Ovarian Cancer After Response To Front-Line Platinum-Based Chemotherapy.

Antonio Gonzalez-Martin,Floor Jennishens Backes,Klaus H. Baumann,Dana Meredith Chase, Mathias Konrad Fehr,Robert L. Coleman,Gilles Freyer,Paul DiSilvestro,Ofer Lavie,Thomas J. Herzog, Domenica Lorusso,Kathleen N. Moore,Mansoor Raza Mirza,Roisin Eilish O'Cearbhaill,Ignace Vergote,Bhavana Pothuri,John Balser,Shefali Agarwal,Bradley J. Monk

GYNECOLOGIC ONCOLOGY（2016）

引用 8|浏览8

暂无评分

摘要

TPS5606Background: Niraparib is a highly selective PARP1/2 inhibitor that induces synthetic lethality in tumor cells with homologous recombination DNA repair deficiencies (HRD). Niraparib is admini...

查看译文

关键词

Synthetic lethality,Chemotherapy,PARP1,Cancer research,Medicine,Advanced ovarian cancer,Double blind,Highly selective,Homologous Recombination DNA Repair,In patient

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要